New FDA Guidelines for COVID-19 Booster Approvals

The Food and Drug Administration (FDA) plans to implement guidelines that will mandate clinical trials before any new COVID-19 boosters can be approved. This information was confirmed by a spokesperson.

These upcoming regulations will put a focus on high-risk groups but will require solid clinical data for individuals under 65 who are considered to be at low risk for COVID-19. This was discussed by Dr. Vinay Prasad, the head of the FDA’s vaccine division, along with Dr. Martin Makary, the agency’s commissioner, in an article published in The New England Journal of Medicine.

“The COVID-19 public health emergency has officially concluded, and we are entering a new phase in our response to the virus,” stated Emily Hilliard, a spokesperson for the Department of Health and Human Services. “The approach of simply approving COVID boosters without updated clinical trial data under the Biden administration is no longer relevant.”

It’s important to note that these guidelines will only affect future booster approvals. Older boosters will still be accessible to individuals of all ages who wish to receive them.

A recent survey from the Center for Excellence in Polling revealed that nearly 90% of voters believe companies should be required to conduct clinical trials prior to approving a COVID-19 booster.

The FDA will still consider approving booster shots for adults aged 65 and older and high-risk individuals, with a commitment to complete a clinical trial afterward. However, for healthy individuals aged 6 months to 64 years, randomized, controlled trials will be necessary for future vaccine approvals.

“The framework published in NEJM offers guidance for a risk-stratified approach that is based on the best available science,” Hilliard remarked. “With the pandemic behind us, it’s crucial to adopt a sensible approach to COVID policy that considers the needs of various populations.”

While most high-income countries limit vaccine recommendations to older adults at higher risk, the U.S. has been following a blanket regulatory framework, allowing broad marketing authorization for anyone over the age of six months, as noted by Vinay and Makary.

FDA officials also mentioned that the benefits of providing multiple doses of the COVID-19 vaccine to younger individuals remain unclear.

“For healthy individuals aged between 6 months and 64 years, who do not have risk factors for severe COVID-19, the FDA expects that randomized, controlled trial data will be needed to assess clinical outcomes before any Biologics License Applications can be approved,” Vinay and Makary stated. “When authorizing a COVID-19 vaccine for high-risk groups, the FDA will push manufacturers to carry out randomized, controlled trials involving healthy adults as part of their post-marketing obligations.”